Focused On-demand Library for DCC-interacting protein 13-beta

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8NEU8

UPID:

DP13B_HUMAN

Alternative names:

Adapter protein containing PH domain, PTB domain and leucine zipper motif 2

Alternative UPACC:

Q8NEU8; B7Z411; B7Z4B0; F5GZG0; F8W1P5; Q8N4R7; Q9NVL2

Background:

DCC-interacting protein 13-beta, also known as Adapter protein containing PH domain, PTB domain and leucine zipper motif 2, plays a pivotal role in cell proliferation, immune response, endosomal trafficking, and cell metabolism. It influences various signaling pathways, including those leading to cell proliferation, immune modulation, and metabolic regulation. This protein's interaction with different membrane receptors, nuclear factors, and signaling proteins underscores its multifunctional nature.

Therapeutic significance:

Understanding the role of DCC-interacting protein 13-beta could open doors to potential therapeutic strategies.